In vivo dopamine pre-synaptic receptors and antioxidant activities in patients with Alzheimer's disease, dementia with Lewy bodies and in controls: A preliminary report

Dementia and Geriatric Cognitive Disorders

Volumn 16, Issue 1, 2003, Pages 46-51

  Tabet, Naji ^a   Walker, Zuzana ^b   Mantle, David ^c   Costa, Durval ^d   Orrell, Martin ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antioxidants; Dementia; Dopamine; Free radicals; Receptors

Indexed keywords

CATALASE; DOPAMINE RECEPTOR; FREE RADICAL; GLUTATHIONE; PRESYNAPTIC RECEPTOR; SUPEROXIDE DISMUTASE;

AGED; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOOXIDATION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; LEWY BODY; MALE; MEDICAL ASSESSMENT; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; STRIATONIGRAL DEGENERATION; TURNOVER TIME;

EID: 0037265947     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069993     Document Type: Article

References (33)

1. Tabet N, Mantle D, Orrell M: Free radicals as mediators of toxicity in Alzheimer's disease: A review and hypothesis. Adverse Drug React Toxicol Rev 2000;19:127-152.
2. Lingor P, Unsicker K, Krieglstein K: GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide. Exp Neurol 2000;163;55-62.
3. Jacobsson SO, Fowler CJ: Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: Effects of NMDA antagonists, antioxidants and MAO inhibitors. Neurochem Int 1999;34:49-62.
4. +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. J Neur Transm 1999;106:477-486.
5. Thomas B, Muralikrishnan D, Mohanakumar KP: In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 2000;852:221-224.
6. Chiueh CC, Krishna G, Tulsi P, Obata T, Lang K, Huang S-J, Murphy DL: Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus. Free Radic Biol Med 1992;13:581-583.
7. Porat S, Simantov R: Bcl-2 and p53: Role in dopamine-induced apoptosis and differentiation. Ann NY Acad Sci 1999;893:372-375.
8. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yanker BA: Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-606.
9. Baba M, Nakajo S, Tu P, Tomita T, Nakaya K, Lee VMY, Trojamowski JQ, Iwatsubo T: Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884.
10. Monteiro HP, Winterbourn CC: 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 1989;38:4177-4182.
11. 2+ transport by dopamine oxidation. Mol Cell Biochem 1999;201:89-98.
12. Duffy S, So A, Murphy TH: Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem 1998;71:69-77.
13. Kabuto H, Yokoi I, Iwata-Ichikawa E, Ogawa N: EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depletion in the mouse striatum by up-regulation of catalase activity. Neurochem Res 1999;24:1543-1548.
14. Moussaoui S, Obinu MC, Daniel N, Reibaud M, Blanchard V, Imperato A: The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 2000;166:235-245.
15. Khaldy H, Escames G, Leon J, Vives F, Luna JD, Acuna-Castroviejo D: Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000;29:100-107.
16. Kalra S, Bergeron C, Lang AE: Lewy body disease and dementia. A review. Arch Int Med 1996;156:487-493.
17. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK: Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's disease: Rostrocaudal distribution. Brain 1999;122:1449-1468.
18. Walker Z, Costa DC, Ince P, McKeith IG, Katona CL: In vivo demonstration of dopamine degeneration in dementia with Lewy bodies. Lancet 1999;354:646-647.
19. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspecies of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. McCord JM, Fridovich L: Superoxide dismutase. J Biol Chem 1969;244:6049-6055.
22. Cohen G, Dembiec D, Marcus J: Measurement of catalase activity in tissue extracts. Anal Biochem 1970;34:30-38.
23. Rice-Evans C, Miller NJ: Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234:279-293.
24. Tabet N, Mantle D, Walker Z, Orrell M: Vitamins, trace elements, and antioxidant status in dementia disorders. Int Psychogeriatr 2001;13:265-275.
25. Khaira HS, Maxwell SRJ, Thomason H, Thorpe GHG, Green MA, Shearman CP: Antioxidant depletion during aortic aneurysm repair. Br J Surg 1996;83:401-403.
26. Rice-Evans CA: Measurement of total antioxidant activity as a marker of antioxidant status in vivo: Procedures and limitations. Free Radic Res 2000;33:S59-S66.
27. Nakamura K, Won L, Heller A, Kang UJ: Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. Brain Res 2000;873:203-211.
28. Spencer JP, Jenner P, Halliwell B: Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
29. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA: Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacoly 1994;17:370-379.
30. Welch K, Yuan J: Releasing the nerve cell killers. Nat Med 2002;8:564-565.
31. Ishisaki A, Hayashi H, Suzuki S, Ozawa K, Mizukoshi E, Miyakawa K, Suzuki M, Imamura T: Glutathione S-transferase Pi is a dopamine-inducible suppressor of dopamine-induced apoptosis in PC12 cells. J Neurochem 2001;77:1362-1371.
32. Tabet N, Mantle D, Walker Z, Orrell M: Endogenous antioxidant activities in relation to concurrent vitamins A, C and E intake in dementia. Int Psychogeriatr 2002;14:7-15.
33. Tabet N, Birks J, Grimley Evans J, Orrell M, Spector A: Vitamin E for Alzheimer's disease (Cochrane review). Cochrane Database Syst Rev 2000;4:CD002854.